<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708500</url>
  </required_header>
  <id_info>
    <org_study_id>P05101</org_study_id>
    <secondary_id>2007-005151-42</secondary_id>
    <nct_id>NCT00708500</nct_id>
  </id_info>
  <brief_title>Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)</brief_title>
  <official_title>A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves treatment with boceprevir or placebo in combination with pegylated
      interferon alfa-2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) in adult
      subjects with chronic hepatitis C (CHC) genotype 1 who demonstrated interferon responsiveness
      (a decrease in hepatitis C virus RNA [HCV-RNA] viral load &gt;=2 log10 by Week 12 or
      undetectable HCV-RNA at end of treatment) but who failed to achieve sustained virologic
      response (SVR) on prior treatment with any combination therapy of peginterferon alpha and
      RBV. This trial includes three arms, one control arm (PEG2b + RBV for 48 weeks) and two
      experimental arms (PEG2b + RBV + boceprevir). One of the experimental arms, Arm 3, consists
      of treatment with all three drugs for 44 weeks after the lead-in. The other experimental arm,
      Arm 2, consists of all three drugs for 32 weeks after the lead-in. Participants in Arm 2 who
      were undetectable for HCV-RNA at Treatment Week 8 will complete treatment at that point.
      Those who were not undetectable for HCV-RNA at Treatment Week 8 will receive an additional 12
      weeks of PEG2b + RBV + boceprevir placebo. It is hypothesized that the addition of a third
      active anti-HCV drug may lead to more rapid viral response than therapy with two drugs, and
      therefore, the addition of boceprevir to PEG2b plus RBV therapy after a 4-week lead-in period
      may allow for both increased rates of SVR and shorter treatment durations (in some
      populations) than treatment with peginterferon plus RBV alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.</measure>
    <time_frame>At Follow-up Week 24</time_frame>
    <description>SVR is defined as undetectable plasma hepatitis C virus RNA (HCV-RNA) at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with chronic hepatitis C (CHC) genotype 1 who failed prior treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.</measure>
    <time_frame>At Follow-up Week 24</time_frame>
    <description>SVR is defined as undetectable plasma HCV-RNA at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with CHC genotype 1 who failed prior treatment.
This key secondary efficacy endpoint was added as per the second protocol amendment on 02 DEC 2009.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Early Virologic Response.</measure>
    <time_frame>At Week 2, 4, 8, or 12</time_frame>
    <description>Having undetectable HCV-RNA at Week 2, 4, 8, or 12 was considered Early Virologic Response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</measure>
    <time_frame>At Follow-up Week 12 and at 72 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Placebo+PEG2b+RBV, x 44 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boceprevir+PEG2b+RBV, Response Guided Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boceprevir+PEG2b+RBV, x 44 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir (SCH 503034)</intervention_name>
    <description>Boceprevir, 200 mg capsules, 800 mg TID PO</description>
    <arm_group_label>Boceprevir+PEG2b+RBV, Response Guided Therapy</arm_group_label>
    <arm_group_label>Boceprevir+PEG2b+RBV, x 44 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated interferon alfa-2b (SCH 54031)</intervention_name>
    <description>PEG2b 1.5 Î¼g/kg/week subcutaneously (SC)</description>
    <arm_group_label>Placebo+PEG2b+RBV, x 44 weeks</arm_group_label>
    <arm_group_label>Boceprevir+PEG2b+RBV, Response Guided Therapy</arm_group_label>
    <arm_group_label>Boceprevir+PEG2b+RBV, x 44 weeks</arm_group_label>
    <other_name>PegIntron</other_name>
    <other_name>PEG2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (SCH 18908)</intervention_name>
    <description>Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).</description>
    <arm_group_label>Placebo+PEG2b+RBV, x 44 weeks</arm_group_label>
    <arm_group_label>Boceprevir+PEG2b+RBV, Response Guided Therapy</arm_group_label>
    <arm_group_label>Boceprevir+PEG2b+RBV, x 44 weeks</arm_group_label>
    <other_name>Rebetol</other_name>
    <other_name>RBV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir placebo</intervention_name>
    <description>Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.</description>
    <arm_group_label>Placebo+PEG2b+RBV, x 44 weeks</arm_group_label>
    <arm_group_label>Boceprevir+PEG2b+RBV, Response Guided Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Qualifying regimen defined as pegylated interferon alfa-2a plus ribavirin or pegylated
             interferon alfa-2b plus ribavirin for a minimum of 12 weeks.

          -  During qualifying regimen, participants must have either a documented undetectable
             HCV-RNA within 30 days of end of treatment (EOT) and a subsequent detectable HCV-RNA
             during follow-up or a documented decline in HCV-RNA by &gt;=2 log10 by Treatment Week 12

          -  Previously documented CHC genotype 1 infection.

          -  Liver biopsy with histology consistent with CHC and no other etiology.

          -  Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6
             months of the Screening Visit (or between Screening and Day 1) with no findings
             suspicious for hepatocellular carcinoma (HCC).

          -  Participants participating in Schering-Plough Research Institute (SPRI) maintenance
             protocols P02570 (NCT00049842) or P02569 (NCT00048724) must have completed the study
             to be eligible for this protocol.

          -  Participants must be &gt;=18 years of age.

          -  Participants must weigh between 40 kg and 125 kg.

          -  Participants and participant's partner(s) must each agree to use acceptable methods of
             contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months
             after last dose of study drug, or longer if dictated by local regulations.

          -  Participants must be willing to give written informed consent.

        Exclusion Criteria:

          -  Coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus
             (Hepatitis B Surface Antigen [HBsAg] positive).

          -  Discontinuation of previous interferon or ribavirin regimen for an adverse event (AE)
             considered by the investigator to be possibly or probably related to ribavirin and/or
             interferon.

          -  Treatment with ribavirin within 90 days and any interferon-alpha within 1 month of
             Screening.

          -  Treatment for hepatitis C with any investigational medication. Prior treatment with
             herbal remedies with known hepatotoxicity.

          -  Treatment with any investigational drug within 30 days of the randomization visit.

          -  Participation in any other clinical trial within 30 days of randomization or intention
             to participate in another clinical trial.

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of clinical ascites, bleeding varices, or hepatic encephalopathy.

          -  Diabetic and/or hypertensive participants with clinically significant ocular
             examination findings.

          -  Pre-existing psychiatric conditions.

          -  Clinical diagnosis of substance abuse of the specified drugs within the specified
             timeframes

          -  Any known pre-existing medical condition that could interfere with the participant's
             participation in and completion of the study.

          -  Evidence of active or suspected malignancy, or a history of malignancy, within the
             last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of
             the skin). Participants under evaluation for malignancy are not eligible.

          -  Participants who are pregnant or nursing. Participants who intend to become pregnant
             during the study period. Male participants with partners who are, or intend to become,
             pregnant during the study period.

          -  Any other condition which, in the opinion of a physician, would make the participant
             unsuitable for enrollment or could interfere with the participant participating in and
             completing the study.

          -  Participants who are part of the site personnel directly involved with this study.

          -  Participants who are family members of the investigational study staff.

          -  Participants who had life-threatening serious adverse event (SAE) during screening
             period.

          -  Protocol-specified hematologic, biochemical, and serologic criteria: Hemoglobin &lt;12
             g/dL for females and &lt;13 g/dL for males; Neutrophils &lt;1500/mm^3 (Blacks: &lt;1200/mm^3);
             Platelets &lt;100,000/mm^3; Direct bilirubin &gt;1.5 x upper limit of normal (ULN).

          -  Serum albumin &lt;lower limit of normal (LLN)

          -  Thyroid-stimulating hormone (TSH) &gt;1.2 x ULN or &lt;0.8 x LLN of laboratory reference
             range, with certain exceptions.

          -  Serum creatinine &gt;ULN of the laboratory reference.

          -  Protocol-specified serum glucose concentrations.

          -  Protocol-specified alpha fetoprotein range.

          -  Prothrombin Time/Partial Thromboplastin Time (PT/PTT) values &gt;10% above laboratory
             reference range.

          -  Anti-nuclear antibodies (ANA) &gt;1:320.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2011</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>154 participants who discontinued during the treatment phase (including those from lead in and/or boceprevir/placebo) entered the follow up phase</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
          <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="P2">
          <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
          <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
        </group>
        <group group_id="P3">
          <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
          <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment (Tx): 4 WEEK LEAD-IN PERIOD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With PEG2b + RBV</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal unrelated to Tx</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal related to Tx</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Tx: RECEIVING BOCEPREVIR/PLACEBO</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal unrelated to Tx</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal related to Tx</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>FOLLOWUP</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrawal unrelated to Tx</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
          <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B2">
          <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
          <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
        </group>
        <group group_id="B3">
          <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
          <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="161"/>
            <count group_id="B4" value="403"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="8.1"/>
                    <measurement group_id="B2" value="52.9" spread="7.4"/>
                    <measurement group_id="B3" value="52.3" spread="7.7"/>
                    <measurement group_id="B4" value="52.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.</title>
        <description>SVR is defined as undetectable plasma hepatitis C virus RNA (HCV-RNA) at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with chronic hepatitis C (CHC) genotype 1 who failed prior treatment.</description>
        <time_frame>At Follow-up Week 24</time_frame>
        <population>FAS = all randomized subjects who received at least one dose of any study medication (Peg, RBV, or boceprevir/placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
            <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
          </group>
          <group group_id="O3">
            <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.</title>
          <description>SVR is defined as undetectable plasma hepatitis C virus RNA (HCV-RNA) at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with chronic hepatitis C (CHC) genotype 1 who failed prior treatment.</description>
          <population>FAS = all randomized subjects who received at least one dose of any study medication (Peg, RBV, or boceprevir/placebo).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="58.6"/>
                    <measurement group_id="O3" value="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>37.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.7</ci_lower_limit>
            <ci_upper_limit>49.1</ci_upper_limit>
            <estimate_desc>Difference in percentage of participants who achieved SVR: experimental minus control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>45.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>33.7</ci_lower_limit>
            <ci_upper_limit>56.8</ci_upper_limit>
            <estimate_desc>Difference in percentage of participants who achieved SVR: experimental minus control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.</title>
        <description>SVR is defined as undetectable plasma HCV-RNA at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with CHC genotype 1 who failed prior treatment.
This key secondary efficacy endpoint was added as per the second protocol amendment on 02 DEC 2009.</description>
        <time_frame>At Follow-up Week 24</time_frame>
        <population>mITT = all randomized subjects who received at least one dose of boceprevir (experimental arms) or boceprevir placebo (control arm).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
            <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
          </group>
          <group group_id="O3">
            <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.</title>
          <description>SVR is defined as undetectable plasma HCV-RNA at Follow-up Week 24. This outcome measure evaluates SVR after treatment with boceprevir and PEG2b plus RBV versus PEG2b plus RBV alone in participants with CHC genotype 1 who failed prior treatment.
This key secondary efficacy endpoint was added as per the second protocol amendment on 02 DEC 2009.</description>
          <population>mITT = all randomized subjects who received at least one dose of boceprevir (experimental arms) or boceprevir placebo (control arm).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="60.9"/>
                    <measurement group_id="O3" value="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>39.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.2</ci_lower_limit>
            <ci_upper_limit>51.0</ci_upper_limit>
            <estimate_desc>Difference in percentage of participants who achieved SVR: experimental minus control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>45.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>33.4</ci_lower_limit>
            <ci_upper_limit>56.8</ci_upper_limit>
            <estimate_desc>Difference in percentage of participants who achieved SVR: experimental minus control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Early Virologic Response.</title>
        <description>Having undetectable HCV-RNA at Week 2, 4, 8, or 12 was considered Early Virologic Response.</description>
        <time_frame>At Week 2, 4, 8, or 12</time_frame>
        <population>FAS = all randomized subjects who received at least one dose of any study medication (Peg, RBV, or boceprevir/placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
            <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
          </group>
          <group group_id="O3">
            <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Early Virologic Response.</title>
          <description>Having undetectable HCV-RNA at Week 2, 4, 8, or 12 was considered Early Virologic Response.</description>
          <population>FAS = all randomized subjects who received at least one dose of any study medication (Peg, RBV, or boceprevir/placebo).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</title>
        <time_frame>At Follow-up Week 12 and at 72 weeks after randomization</time_frame>
        <population>FAS = all randomized subjects who received at least one dose of any study medication (Peg, RBV, or boceprevir/placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
            <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
          </group>
          <group group_id="O3">
            <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
            <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</title>
          <population>FAS = all randomized subjects who received at least one dose of any study medication (Peg, RBV, or boceprevir/placebo).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-Up Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Weeks Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo+PEG2b+RBV, x 44 Weeks</title>
          <description>Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="E2">
          <title>Boceprevir+PEG2b+RBV, Response Guided Therapy</title>
          <description>Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion.</description>
        </group>
        <group group_id="E3">
          <title>Boceprevir+PEG2b+RBV, x 44 Weeks</title>
          <description>Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PANCREATITIS NECROTISING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HOMICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA REPAIR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E2" events="117" subjects_affected="70" subjects_at_risk="162"/>
                <counts group_id="E3" events="125" subjects_affected="75" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" events="60" subjects_affected="23" subjects_at_risk="162"/>
                <counts group_id="E3" events="43" subjects_affected="23" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="23" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="162"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" events="59" subjects_affected="38" subjects_at_risk="162"/>
                <counts group_id="E3" events="59" subjects_affected="40" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="80"/>
                <counts group_id="E2" events="89" subjects_affected="72" subjects_at_risk="162"/>
                <counts group_id="E3" events="99" subjects_affected="68" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="162"/>
                <counts group_id="E3" events="33" subjects_affected="24" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" events="43" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E3" events="59" subjects_affected="38" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="36" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E2" events="94" subjects_affected="56" subjects_at_risk="162"/>
                <counts group_id="E3" events="63" subjects_affected="50" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="59" subjects_affected="40" subjects_at_risk="80"/>
                <counts group_id="E2" events="137" subjects_affected="87" subjects_at_risk="162"/>
                <counts group_id="E3" events="115" subjects_affected="92" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E2" events="51" subjects_affected="41" subjects_at_risk="162"/>
                <counts group_id="E3" events="44" subjects_affected="38" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="162"/>
                <counts group_id="E3" events="33" subjects_affected="16" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="162"/>
                <counts group_id="E3" events="41" subjects_affected="36" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E2" events="58" subjects_affected="45" subjects_at_risk="162"/>
                <counts group_id="E3" events="67" subjects_affected="48" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E3" events="19" subjects_affected="15" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" events="38" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E3" events="56" subjects_affected="46" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="162"/>
                <counts group_id="E3" events="53" subjects_affected="39" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E2" events="82" subjects_affected="46" subjects_at_risk="162"/>
                <counts group_id="E3" events="42" subjects_affected="35" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E3" events="36" subjects_affected="26" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="79" subjects_affected="70" subjects_at_risk="162"/>
                <counts group_id="E3" events="86" subjects_affected="72" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="50" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E2" events="95" subjects_affected="69" subjects_at_risk="162"/>
                <counts group_id="E3" events="82" subjects_affected="64" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="162"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E3" events="39" subjects_affected="28" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="33" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E2" events="65" subjects_affected="50" subjects_at_risk="162"/>
                <counts group_id="E3" events="62" subjects_affected="47" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E3" events="59" subjects_affected="40" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" events="42" subjects_affected="29" subjects_at_risk="162"/>
                <counts group_id="E3" events="46" subjects_affected="40" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="162"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" events="44" subjects_affected="42" subjects_at_risk="162"/>
                <counts group_id="E3" events="30" subjects_affected="29" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="40" subjects_affected="35" subjects_at_risk="162"/>
                <counts group_id="E3" events="45" subjects_affected="37" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" events="41" subjects_affected="31" subjects_at_risk="162"/>
                <counts group_id="E3" events="47" subjects_affected="31" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E3" events="40" subjects_affected="24" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

